M. Kruithof-de Julio

The paper shows that mechanotransduction via TAZ and cytoskeletal tension promotes prostate cancer stem cell metastasis and identifies a YAP/TAZ inhibitor as a potential therapeutic target.

This study uses contrast-enhanced microCT to visualize vasculature in bone and peri-implant tissues across animal models, demonstrating dual-energy imaging for distinguishing bone from contrast agents.

This study identifies GATA3 and MDM2 as synthetic lethal in ER-positive breast cancers, showing MDM2 inhibition can target GATA3-deficient tumors via the PI3K/Akt/mTOR pathway.

This study uses bladder cancer patient-derived organoids to model disease stages and therapy response, identifying markers of resistance and sensitivity.

The paper shows that minor intron splicing efficiency increases in castration-resistant prostate cancer and that inhibiting the minor spliceosome reduces tumor burden.

This study identifies host cell master regulators affected by SARS-CoV-2 and develops a method to find drugs that reverse their inactivation without harming beneficial immune responses.

This study develops a patient-derived xenograft (PDX) model of prostate cancer that mimics disease stages and identifies drug sensitivities in metastatic cases.

The paper investigates the role of mSWI/SNF complexes in NEPC lineage plasticity using patient data and cell models, finding deregulated subunits and SMARCA4 overexpression linked to aggressive disease.

The paper identifies tenascin C as a stromal marker associated with metastasis in prostate cancer xenograft models and shows its prognostic potential in patient samples.